Multinational pharmaceutical companies report the third quarter results

[market analysis of chinapharma.com] in recent days, multinational pharmaceutical companies have successively released the third quarter financial statements, which are happy and worried Among them, Johnson & Johnson's single quarter revenue exceeded 19 billion US dollars, Abbott's revenue grew strongly, Amgen allied with local pharmaceutical companies and Novartis separated the eye care department, Gilead sent sofibway to medical insurance, and Lilly, BMS, Xinji and Baijian saw a single digit growth (multinational pharmaceutical companies announced their third quarter financial statements) in late October, major multinational pharmaceutical companies announced their third quarter financial statements R & D, M & A and business transformation are all looking for new growth points In the pharmaceutical industry, where products are the king, the success of a clinical trial and the approval of a new product will have a great impact on the performance and share price In the fierce competition situation, while keeping the bottom line of products, the enterprise must also adapt to the new environment, adjust the route in time with a keen eye, and grasp the direction ahead 1 J & J's single quarter revenue broke $19 billion again, rising to $19.65 billion in the third quarter from $17.77 billion in the quarter of 2017 The operating revenue of J & J continued to rise at an average growth rate of 5.17% per quarter Compared with the same period in 2016, the growth rate of 10.27% was achieved in the third quarter of 2017; this is also that since the second quarter of 2014 (US $19.49 billion), the single quarter revenue of J & J exceeded US $19 billion again The report card is directly related to J & J's $30 billion acquisition of actelion Actelion, which was formally acquired in June this year, brings Johnson & Johnson a series of heavy drugs for pulmonary hypertension and drugs for lymphoma treatment, two of which will have sales of more than 4 billion US dollars in 2020 With the addition of actelion, Johnson & Johnson's competitive influence in the field of biological imitations will be more significant than expected From the perspective of business distribution, the sales performance of pharmaceutical products has led the strong growth outside of Johnson & Johnson's acquisition business The sales volume of immune disease drugs increased by 6% year on year, and that of tumor disease drugs increased by 25% year on year The medical device business that once supported the stable growth of Johnson & Johnson is also reversing the decline in 2016, with the growth of vision health care medical devices as high as 47.6% Johnson & Johnson's third quarter profit fell more than 10% as operating costs and R & D expenses rose According to the financial report data, the operating cost of J & J in the third quarter reached a historical high of $6.9 billion, with R & D expenses of $2.57 billion 2 Abbott's revenue grew strongly In the third quarter, Abbott's global sales reached US $6.8 billion, an increase of 28.8% over the same period last year Excluding factors such as M & A and exchange rate, the operating revenue increased by 5.6% After adjustment, the income continued to maintain double-digit growth The company made a profit of $603 million, compared with a loss of $329 million in the same period of the previous year In the third quarter, Abbott's business sectors all performed well The global sales volume of medical device business is nearly 2.6 billion US dollars, up 5.6% year on year Thanks to Abbott's innovative research and development of the revolutionary glucose monitoring system, the global sales of its diabetes care sector is up 19.1% year on year The global sales of nutrition business in the third quarter increased by 0.8% year on year to US $1.8 billion Among them, the growth of infant nutrition sales mainly comes from the U.S market In the third quarter of the pharmaceutical business, global sales reached US $1.2 billion, up 14.3% year on year Among them, sales in emerging markets, including Brazil, Russia, India and China, increased by 18% year-on-year, accounting for more than 75% of global sales In the third quarter, the global sales of diagnosis business reached US $1.3 billion, up 5.2% year on year Globally, Abbott will continue to focus on the initial layout of the alinitytm diagnostic system during the quarter Mr Bai Qianli, chairman and CEO of Abbott, said: "we are very satisfied with the company's current performance New products have been on the market steadily, and sales have increased accordingly Earnings per share for the year is expected to reach the upper limit of the forecast range " Amgen, a local pharmaceutical company, and Novartis stripped off the eye care department, announced that Amgen had a profit of $2.02 billion in the third quarter, which was the same as that of the same period last year, with revenue down 1% to $5.77 billion from $5.81 billion last year During the reporting period, Amgen has taken many actions in the development of new anticancer drugs In January, it entered into a deal worth more than US $1.3 billion with Germany's imatics Biotechnology Co., Ltd to develop the next generation of T-cell double specific immunotherapy for multiple cancers, which will receive US $30 million in upfront costs by providing technology and targets Good news keeps coming After submitting the review request in Europe at the beginning of this year, in August, the Herceptin generic drug jointly developed by Amgen and Elgin was submitted to FDA for review Herceptin is a Roche blockbuster with an annual sales volume of nearly 7 billion US dollars In September, the FDA approved mvasi, a biological similar drug developed by Amgen and Elgin, which is also the approved Avastin biological similar drug of Roche In October, the results of a phase 3 clinical trial conducted by Amgen for multiple myeloma reached the end point With the expiration of many original research biopharmaceuticals, enterprises have distributed bio similar drugs, and the opening of 10 billion market is changing the international and domestic pharmaceutical industry pattern An Jin, who is sure of this opportunity, has taken the initiative In October, it entered into a strategic alliance with the local enterprise Xiansheng on bio similar drugs Amgen continued to be responsible for the joint development, marketing license application and production of four bio similar drugs; Xiansheng was responsible for the distribution and commercialization of bio similar drugs in the Chinese market Cooperation with local pharmaceutical companies represents the core strategy of amjin to seize the Chinese bio pharmaceutical market Since the beginning of the year, Amgen's share price has risen by 21%, and its closing price on the third quarter financial report day was $177.50, up 12% in the past 12 months At present, the market value is 129.517 billion yuan Novartis achieved a 2% increase in sales in the third quarter "Novartis group has shown solid growth in all business areas," said Jiang Muzhong, executive director of Novartis group Alcon has achieved strong growth in sales and core business revenue " According to the Novartis report, in the third quarter, Novartis' tumor sales increased by 11% (excluding Greaves), Alcon's overall performance increased by 7%, Sanders' sales outside the U.S market increased by 1%, and Novartis' performance climbed The approval of multiple new product connections also makes Novartis optimistic in the capital market On August 30, FDA announced that Novartis car-t cell therapy was officially launched for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in children and adolescents, the trade name is kymriah, which became the global approved car-t cell therapy; rydapt for the treatment of FLT3 mutant acute myeloid leukemia (AML) and advanced systemic mastocytosis was approved in the European Union; Rixathon, a bioequivalent drug, has entered the FDA approval process; clarion autonome, an Alcon intraocular lens, has been approved in the European Union With the release of the financial report, Novartis also said that the process of separating Alcon's eye care department from the company has made "significant progress", which will be achieved in the first half of 2019 Alcon's eye care division saw a 7% increase in sales in the third quarter, and Novartis hopes to create additional shareholder value by creating an independent company through capital market exports However, since 2014, Alcon's performance has continued to decline and its competitiveness is not strong From the beginning of 2016, Novartis's speculation about selling Alcon continued to spread At that time, analysis believed that even if Alcon's business turned into profit, Alcon would still be sold In November 2016, Novartis announced to give up the clinical trial of autofocus contact lenses, which is led by Alcon's eye care department Perhaps, the separation of the eye department is the step to divest Alcon 4 Gilead: the third quarter of 2017 (Q3) financial report of Gilead, which sent sofibway to medical insurance, showed that due to the constant erosion of its hepatitis C virus (HCV) product market by generic drugs, the global operating revenue of Gilead Q3 suffered a huge decline of 13% year-on-year, falling to $6.51 billion However, its HIV and hepatitis B virus (HBV) drugs continued to grow during Q3 Although the performance is not satisfactory, gillide has made some achievements in the third quarter One is that in August this year, Holly spent 11 billion dollars to acquire kit, the leading immunotherapy company, and successfully ranked in the global car-t therapy echelon Kit's car-t therapy has been approved by the US FDA for listing Another important achievement is that Gilead's hepatitis C drug, suofibuvir, was approved for marketing in China in September this year In Q3 revenue conference call, Geely CEO John Milligan said, "this is a product that Geely directly launched in China." According to Milligan, Gilead has also prepared an application for the listing of the HBV drug vemlidy In addition, in the near future, they plan to submit applications for the HCV treatment drugs harvoni and epclusa At present, Gilead is preparing to build its own medical team and market access team in China Kevin young, operations officer, pointed out that Gilead has started to prepare for the listing of sofibway in the private market, and will try to push sofibway from the private market to the provincial reimbursement scope in 2018 In the next round of national health insurance catalog adjustment, we will try our best to get sovaldi, harvoni, epclusa and vemlidy into health insurance 5 The single digit growth of Lilly, BMS, Xinji and Baijian Lilly's revenue in the third quarter rose in single digits, up 9% from $5.19 billion to $5.66 billion, but its net profit increased significantly to 40% year on year The increase in performance was mainly driven by 10 new products, and the revenue of the pharmaceutical business increased by 10%, including dulaglutide, insulin glargine, engeliejin and other new drugs accounted for 22% of the total revenue, and the sales volume of new drugs increased by 14% Dulaglutide, a drug used to treat diabetes, is a big selling drug of Lilly, with revenue of 527 million US dollars this quarter, up 117% year on year The global revenue of eparinet, a new diabetes drug jointly launched by Lilly and bringer Ingelheim, was US $127 million, up 168% year on year While new drugs boost performance, Lilly's products are also under pressure from generic drugs The drug protection of insulin ubilin has expired In September this year, Sanofi's generic drug plan has been approved by FDA If the plan is carried out as scheduled, Lilly's performance in 2019 will be under pressure Due to the change of sales mode, sales volume of ubilin outside the United States fell 23% in the third quarter Recently, Lilly is in the process of business restructuring, and management said that it may split its animal health department In September, Lilly announced 3500 job cuts, and its treasurer and President of production will retire at the end of the year But since the beginning of the year, Lilly's share price has risen 11.3 US dollars, or 15.36% At present, Lilly's P / E ratio is 23.78, which reflects the optimism of the market Bristol Myers Squibb announced that the company's revenue rose 7% to $5.25 billion in the third quarter, and its profit fell 30% to $845 million, compared with $1.2 billion in the same period of the previous year, which was lower than the expectation of Wall Street Sales of the cancer drugs opdivo and dupliciti were better than expected in the third quarter, according to the BMS announcement The decrease of net profit is related to BMS increasing R & D investment In recent years, BMS's investment in R & D accounts for more than 30% of its revenue, and it is in the industry Its multicenter clinical research in China focuses on the field of cancer and explores joint treatment schemes.